A commonly used inexpensive drug for the treatment of gout has been found to have the potential to reduce hospitalization between Kovid-19 patients and the need for additional oxygen.
The results of new research on colchicine conducted in Brazil came after an international trial published on Wednesday found that it reduced hospitalizations and deaths by more than 20% among Kovid-19 patients.
Colchicine, which is used to treat rheumatic diseases, was formulated by researchers in a government-funded trial of Quebec and the Philosophist as likely to be the first oral drug for the treatment of Kovid-19.
The latest tests, funded by the foundation and Brazilian authorities, suggested that the drug could reduce the body’s inflammatory response and help protect cells from damage by flashing blood vessel walls.
According to a report on a small clinical trial published in the online journal RMD Open published by the British Medical Journal, “cocchin has proven to be beneficial for the treatment of patients hospitalized with coccidin-19.” .
Researchers said it was not associated with serious side effects, such as heart or liver damage or immune system suppression, factors that are sometimes associated with some other drugs used to treat Kovid.
He said that the need for oxygen therapy and reduction in length of hospital stay was not only good for patients, but they also cut the cost of healthcare and the need for hospital beds also increased.
However, they also cautioned that the trial included only a small number of patients, and they were unable to determine whether colchicine could avoid the need for intensive care or reduce the risk of death .
Brazil has been particularly in trouble due to the epidemic, while health workers in the country’s largest state have been begging for help and oxygen supply after the Kovid infection intensified.
While coccinin has been used to treat and prevent inflammatory conditions, a feature of some Kovid infections, researchers wanted to find out if using it could reduce the need for extra oxygen or longer stays in hospitals .
The research was carried out between April and August of last year, when severe Kovid-19s from 75 were hospitalized, randomly assigned to receive different levels of colchicine.
Results were based on 72 patients. It was found that patients requiring an average length of oxygen therapy were four days to be treated with additional cholecycine, compared to 6.5 days for those receiving standard types of treatment.
The average length of hospital stay was seven days for the colchicine group compared to nine for the second group.